SCR-LIP-000569 · Claim · machine-readable JSON →

A new disease-specific Patient Benefit Index for lymphedema and lipedema (PBI-L) was validated (n=301 cross-sectional, n=82 RCT), yielding a mean global benefit score of 2.2±1.0 and correlating with disease-specific HRQoL (FLQA-LK, r=0.31) but not with change in generic EQ-5D-3L.

This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
moderate (GRADE)
Evidence
1 source(s)
Dates
2026-11-17 → 2026-11-17

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17

Evidence over time

2014Evaluation of Patient-relevant Outcomes of Lymphedema and Lipedema Treatment: Development and Validation of a New Benefit Tool (2014) · contextual

Evidence (1)

Context (PECO)

Populationpatients with lymphedema and lipedema (n=301 cross-sectional; n=82 RCT)
Conditionlipedema
ExposurePBI-L treatment benefit instrument (vs HRQoL measures)
Comparatorgeneric vs disease-specific HRQoL instruments
Outcometreatment benefit, HRQoL (FLQA-LK, EQ-5D-3L)
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log